1.Medizinische Klinik und Poliklinik I,Rheinische Friedrich-Wilhelms-Universit?t,Bonn,Germany;2.Medizinische Klinik II,Klinikum Aschaffenburg,Germany;3.Department of Gene and Cell Medicine,Mount Sinai School of Medicine,New York,USA
Abstract:
Background
Modulation of the immune system by genetically modified lymphoma cell vaccines is of potential therapeutic value in the treatment
of B cell lymphoma. However, the anti-tumor effect of any single immunogene transfer has so far been limited. Combination
treatment of recombinant IL-2 and IL-12 has been reported to be synergistic for inducing anti-tumor responses in solid tumors
but the potential of IL-2/IL-12 gene modified B cell lymphoma cells has not been explored yet.